January 20, 2022
2 min watch
Save
VIDEO: Expert discusses potential practice-changing therapy for cold agglutin disease
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Allyson Pishko, MD, MSCE, discussed the results of the CADENZA study presented at ASH Annual Meeting and Exposition.
According to the abstract, this randomized, placebo-controlled phase 3 study investigated the efficacy and safety of sutimlimab (Sanofi) among patients with cold agglutin disease.
“They actually showed very, very rapid responses to patients’ improvement in their hemoglobin and these responses really sustained over time,” said Pishko, assistant professor of medicine at the University of Pennsylvania.
References
- Roesth A, et al. Abstract #349. Presented at: ASH Annual Meeting & Exposition; Dec. 11-14, 2021; Atlanta.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Pishko reports receiving research funding from Sanofi Genzyme.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.